The incidence of recurrent Clostridioides difficile infection was lower among at-risk patients on antibiotics for other ...

In the first placebo-controlled study of vaporized cannabis for acute migraine, patients report greater relief from pain and ...

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in ...

Takeda announces positive results from two pivotal phase 3 studies of oveporexton in narcolepsy type 1: Osaka Wednesday, July 16, 2025, 16:30 Hrs [IST] Takeda, a global company fo ...

Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia ...

Monjuvi added to Rituxan and Revlimid extended progression-free survival from 14 to 22 months in follicular lymphoma, ...

Suven Life Sciences has a portfolio of advanced-stage clinical candidates and research programs designed for CNS disorders ...

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

First patient dosing in Company’s Phase 2b trial marks pivotal milestone in phage therapy development program targeting ...

A 30-day course of antibiotics after robot-assisted radical cystectomy appears to eliminate UTIs and reduce costs of care.

The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing ...

There are a variety of supplements available that may help keep your cortisol levels in check—particularly when combined with ...